

## **Resignation of Joint Company Secretary**

**Neurotech International Limited (ASX: NTI)** ("NTI" or "the Company"), advises that Mrs Erlyn Dawson has resigned as Joint Company Secretary with immediate effect.

The Company thanks Mrs Dawson for her support of the Board during her time with the Company.

Ms Alessandra Gauvin will continue in her role as sole Company Secretary and person responsible for communications with ASX in relation to Listing Rule matters under ASX Listing Rule 12.6.

## Authority

This announcement has been authorised for release by Tom Duthy, Executive Director of Neurotech International Limited.

## Investors:

Dr Thomas Duthy Executive Director td@neurotechinternational.com +61 (0)402 493 727

## **About Neurotech**

**Neurotech International Limited (ASX:NTI)**) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <u>http://www.neurotechinternational.com</u>.

Neurotech International Ltd Suite 5 CPC, 145 Stirling Highway Nedlands, Western Australia 6009 T: +61 (8) 9389 3130
E: info@neurotechinternational.com
W: neurotechinternational.com

ABN: 73 610 205 402 ASX: NTI